Healthcare Providers & Services - Dialysis and Kidney Care
Strategic Profile
As of early February 2026, the company is being hailed as one of the top-performing large-cap stocks of the year. With a clarified regulatory horizon and massive share buybacks boosting earnings per share (EPS), DaVita has proven that the death of dialysis was greatly exaggerated. DaVita has embraced a collaboration with Elara Caring, paving ways into the kidney-specific, home-based care landscape and bolstering their intent to remain at the forefront of patient-specific healthcare solutions.
Cyborg Score Rationale
In February 2026, DVA reached new all-time highs as the market digested projections for 2026 adjusted EPS of $13.60 to $15.00, well above the $12.65 analyst consensus. Clinical data released at the end of 2025 showed that GLP-1 drugs reduce dialysis patient mortality by 17%, meaning patients stay in the system longer, increasing the lifetime value per patient. The company demonstrates operational excellence with strong EPS guidance and strategic positioning in kidney care.
Top Insights
In February 2026, DVA reached new all-time highs as the market digested a massive upward revision in its 2026 earnings guidance
In 2025, the company repurchased roughly 15% of its outstanding shares, a move that has historically supercharged its EPS growth even when organic revenue growth is modest
Following a mid-2025 incident that cost the company $45 million in remediation, DaVita remains a target for state-sponsored and criminal cyber actors given the sensitive nature of patient data
The aging Baby Boomer demographic continues to provide a tailwind of new CKD diagnoses, ensuring a steady long-term patient pipeline
Named Competitors
Fresenius Medical Care — Global dialysis and kidney care provider
Renal Advantage Inc. — Dialysis provider and integrated kidney care
Dialysis Corporation of America — Regional dialysis services
Recent Developments
(February 2026) Strong Q4 2025 earnings beat and all-time high stock price following upward 2026 EPS guidance
(February 2026) Stock trading up 21.52% following Q4 earnings triumph and strategic initiatives
(December 2025) Appointments of Chief People Officer and Chief Strategy Officer underscoring commitment to innovation
(October 2025) Launch of two groundbreaking kidney care initiatives
Open the full interactive DaVita Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.